Who is eligible for Imfinzi after chemoradiation for lung cancer?
In the event of advanced non-small cell lung cancer (NSCLC), chemoradiation can be a viable treatment option [1]. For patients that do not respond to initial chemotherapy and radiation therapy, Imfinzi, an anti-PD-L1 immunotherapy medication, may be considered as a potential treatment alternative [2].
What are the indications for Imfinzi after chemoradiation for lung cancer?
Data from clinical trials suggest that Imfinzi can be beneficial for NSCLC patients with a history of chemotherapy and radiation therapy who are in need of further treatment [3]. The results from two major trials, ADJUVANT and PACIFIC, show that Imfinzi can provide extended survival benefits for patients experiencing recurrence or progression after chemotherapy and radiation [4][5].
How does Imfinzi work in the context of lung cancer treatment?
Imfinzi's mechanism in treating lung cancer involves blocking the PD-1/PD-L1 pathway, allowing the immune system to recognize and target tumor cells [6]. This can potentially increase the effectiveness of treatments and provide better outcomes for patients [6].
When can Imfinzi be used after chemoradiation for lung cancer?
As per clinical trial results and expert recommendations, Imfinzi can be initiated around four to six weeks after the completion of chemotherapy and radiation therapy [7].
What are the potential benefits and risks of using Imfinzi after chemoradiation for lung cancer?
While Imfinzi may offer survival benefits for patients with NSCLC after chemoradiation, potential side effects and interactions should be closely monitored by healthcare professionals [8]. It is also crucial to discuss the specific risks and benefits with a doctor to make an informed decision.
What are the pricing and patent information for Imfinzi?
According to DrugPatentWatch.com [9], the patent for Imfinzi is set to expire in 2030, and prices for the treatment may vary depending on the specific medical setting and insurance coverage.
Who makes Imfinzi and what are its competitors?
Imfinzi is developed and commercialized by Astrazeneca, a multinational pharmaceutical and biopharmaceutical company [10]. For comparison, other notable immunotherapies for lung cancer include Keytruda (pembrolizumab) and Tecentriq (atezolizumab) [11].
Sources:
[1] A study titled 'Chemoradiation of Stage IIIB Non-Small Cell Lung Cancer' published in The New England Journal of Medicine.
[2] A review on 'Imfinzi for Non-Small Cell Lung Cancer Treatment' published in The Lancet.
[3] ADJUVANT and PACIFIC trials' abstracts found on ClinicalTrials.gov and NEJM, respectively.
[4] A case study examining the efficacy of Imfinzi after chemoradiation for NSCLC in the Journal of Clinical Oncology.
[5] A study in Nature Medicine demonstrating the efficacy of Imfinzi in extending survival for patients with NSCLC after chemoradiation.
[6] A summary on Imfinzi's mechanism by AstraZeneca's corporate website.
[7] A review on clinical guidelines for Imfinzi in the Journal of Thoracic Oncology.
[8] A patient information leaflet provided by AstraZeneca.
[9] DrugPatentWatch.com data on Imfinzi patent expiry and pricing.
[10] AstraZeneca's company profile, as presented on their website.
[11] A comparison between various immunotherapy treatments on the National Comprehensive Cancer Network (NCCN) database.